Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells

Cellular Immunology

Volumn 279, Issue 1, 2012, Pages 96-102

  Yang, Shuan Suo ^a   Li, Ruogu ^b   Qu, Xinkai ^b   Fang, Weiyi ^b   Quan, Zhe ^a  

^a Fengxian Central Hospital   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Atorvastatin; Innate immune system; NF B; Proinflammatory cytokines; Toll like receptor

Indexed keywords

ATORVASTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKEMIA; LIPOPOLYSACCHARIDES; MONOCYTES; NF-KAPPA B; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871642968     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.09.008     Document Type: Article

References (39)

1. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
2. Weissberg P.L., Bennett M.R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:1928-1929.
3. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
4. Skalen K., Gustafsson M., Rydberg E.K., Hulten L.M., Wiklund O., Innerarity T.L., Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
5. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 139:205-222.
6. Nilsson J., Fredrikson G.N. Atherosclerosis. Autoimmunity 2004, 37:351-355.
7. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. J Cell Sci 2006, 124:783-801.
8. Pasare C., Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005, 560:11-18.
9. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
10. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
11. Liu Y., Yu H., Zhang Y., Zhao Y. TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med Hypotheses 2008, 70:314-316.
12. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1161.
13. Coward W.R., Marei A., Yang A., Vasa-Nicotera M.M., Chow S.C. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006, 176:5284-5292.
14. Ortego M., Bustos C., Hernandez-Presa M.A., Tunon J., Diaz C., Hernandez G., Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147:253-261.
15. Methe H., Kim J.O., Kofler S., Nabauer M., Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005, 25:1439-1445.
16. Schwartz A.L., Malgor R., Dickerson E., Weeraratna A.T., Slominski A., Wortsman J., Harii N., Kohn A.D., Moon R.T., Schwartz F.L., Goetz D.J., Kohn L.D., McCall K.D. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res 2009, 15:4114-4122.
17. Dasu M.R., Park S., Devaraj S., Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009, 150:3457-3464.
18. Sanchez-Lemus E., Benicky J., Pavel J., Larrayoz I.M., Zhou J., Baliova M., Nishioku T., Saavedra J.M. Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1376-1384.
19. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
20. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 1992, 24:145-149.
21. Abreu M.T., Vora P., Faure E., Thomas L.S., Arnold E.T., Arditi M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001, 167:1609-1616.
22. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002, 168:554-561.
23. Faure E., Thomas L., Xu H., Medvedev A., Equils O., Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001, 166:2018-2024.
24. Schoneveld A.H., Hoefer I., Sluijter J.P., Laman J.D., de Kleijn D.P., Pasterkamp G. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 2008, 197:95-104.
25. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice. mutations in Tlr4 gene. J Cell Sci 1998, 282:2085-2088.
26. Naiki Y., Sorrentino R., Wong M.H., Michelsen K.S., Shimada K., Chen S., Yilmaz A., Slepenkin A., Schroder N.W., Crother T.R., Bulut Y., Doherty T.M., Bradley M., Shaposhnik Z., Peterson E.M., Tontonoz P., Shah P.K., Arditi M. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J Immunol 2008, 181:7176-7185.
27. Yang J., Huang C., Yang J., Jiang H., Ding J. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: a key role for TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2010, 345:189-195.
28. Guo F., Zhou Z., Dou Y., Tang J., Gao C., Huan J. GEF-H1/RhoA signalling pathway mediates lipopolysaccharide-induced intercellular adhesion molecular-1 expression in endothelial cells via activation of p38 and NF-kappaB. Cytokine 2012, 57:417-428.
29. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
30. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2:947-950.
31. Niessner A., Steiner S., Speidl W.S., Pleiner J., Seidinger D., Maurer G., Goronzy J.J., Weyand C.M., Kopp C.W., Huber K., Wolzt M., Wojta J. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006, 189:408-413.
32. Pleiner J., Schaller G., Mittermayer F., Zorn S., Marsik C., Polterauer S., Kapiotis S., Wolzt M. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004, 110:3349-3354.
33. Neurauter G., Wirleitner B., Laich A., Schennach H., Weiss G., Fuchs D. Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003, 131:264-267.
34. Zeuke S., Ulmer A.J., Kusumoto S., Katus H.A., Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002, 56:126-134.
35. Wang Y., Zhang M.X., Meng X., Liu F.Q., Yu G.S., Zhang C., Sun T., Wang X.P., Li L., Wang Y.Y., Ding S.F., Yang J.M., Zhang Y. Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells. Am J Physiol Heart Circ Physiol 2011, 300:H1743-H1752.
36. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
37. Fessler M.B., Parks J.S. Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling. J Immunol 2011, 187:1529-1535.
38. Triantafilou M., Miyake K., Golenbock D.T., Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002, 115:2603-2611.
39. Chansrichavala P., Chantharaksri U., Sritara P., Ngaosuwankul N., Chaiyaroj S.C. Atorvastatin affects TLR4 clustering via lipid raft modulation. Int Immunopharmacol 2010, 10:892-899.